“Global Leukemia Drug Market, Drug Price, Patent, Dosage & Clinical Trials Insight 2025” Report Highlights:
- Global Leukemia Drug Market Opportunity: More Than US$ 22 Billion by 2025
- Comprehensive Insight on Leukemia Drug Clinical Trials: 633 Drugs
- Leukemia Drug Clinical Pipeline Insight by Company, Drug Class, Patent
- Comprehensive Clinical Insight on Marketed Leukemia Drug: 77 Drugs
- Marketed Leukemia Drug Insight by Drug Class: Availability, Dosage & Price Analysis
- Global Drug Development Partnerships & Collaboration Insight
Download Report: https://www.pnspharma.com/reports/global-leukemia-drug-market-drug-price-patent-dosage-clinical-trials-insight-2025
Table of Contents
- Introduction to Leukemia
1.1 Overview
1.2 History: Initial Description & Origin of Leukemia
- Relevance of Leukemia Therapeutics in Pharmaceutical Market
- Commercially Available Treatments & its Impact on the Global Leukemia Therapeutics Market
- Leukemia Therapeutics Market Growth with Chemotherapy Drugs
4.1 Overview
4.2 Mechanism of Action of Chemotherapy Drugs towards Leukemia Cancer Cells
- Immunotherapy Candidates Promising Attribute towards Global Leukemia Therapeutics Market
5.1 Overview
5.2 Mechanism of Action of Immunotherapy against Leukemia Cells
- Small Molecule Cancer Drugs Evolving Global Leukemia Therapeutics Market
6.1 Overview
6.2 Mechanism of Action of Small Molecule Cancer Drugs towards Leukemia
Treatment
- Global Impact of Bone Marrow Transplantation on Leukemia Therapeutics Market
7.1 Overview
7.2 Mechanism of Action of Bone Marrow Transplantation in Leukemia Patients
- Radiation Therapy Impact on the Global Leukemia Therapeutics Market Growth
8.1 Overview
8.2 Mechanism of Action of Radiation Therapy for Leukemia Treatment
- Ongoing Clinical Research Development for Leukemia Therapeutics
9.1 UCLA to Combine Two Therapies to Leukemia Treatment Platform Available
9.2 CAR-T Cell Trials for Common Leukemia & Lymphoma Types led by UCLA
9.3 LILRB4, A New Potential Target for Leukemia Focused by UT Southwestern
Researchers
9.4 Phase Ib/II Trial Result for IDH1-Mutated Acute Myeloid Leukemia by University
of Texas M. D. Anderson Cancer Center
9.5 CAR-NK Cell Therapy for Clinical Trials Results for chronic lymphocytic
leukemia by The University of Texas MD Anderson Cancer Center
9.6 Takeda’s Phase II Trial of Pevonedistat & Azacitidine in Patients with Leukemia
- Global Partnerships & Collaboration Insights for Development of Leukemia Therapeutics
10.1 Piramal Pharma Solutions & BerGenBio to Undergo FDA Fast Track Leukemia
Treatment Development
10.2 Pascal Biosciences and Y-Biologics to Develop Bispecific Antibody for
Leukemia Treatment
10.3 Daiichi Sankyo & MD Anderson Collaboration for Accelerated Development of
Acute Myeloid Leukemia Therapies
10.4 Merck & Harvard to Undergo Collaboration for Developing Small Molecule
Drugs for Acute Myeloid Leukemia
10.5 JZP-458 Pivotal Phase 2/3 for Acute Lymphoblastic Leukemia Study Initiation
Announcement by Jazz Pharmaceuticals
- Global Leukemia Therapeutics Market Market Overview
- Regional Leukemia Therapeutics Market Analysis
12.1 US
12.2 European Union
12.3 Asia
12.4 Middle East & Africa
- Global Leukemia Drug clinical Trials Overview
13.1 By Phase
13.2 By Country
13.3 By Drug Class
13.4 By Company/Clinic
13.5 By Patient Segment
- Antineoplastic Drugs for Leukemia – Availability, Dosage & Price Analysis
14.1 Azacitidine (Vidaza)
14.2 Venetoclax (Venclexta)
14.3 Enasidenib (Idhifa)
14.4 Tretinoin (Vesanoid)
14.5 Histamine Dihydrochloride Injection (Ceplene)
14.6 Ubenimix (Bestatin)
14.7 Arsenic Trioxide (Trisenox)
14.8 Tamibarotene (Amnolake)
14.9 Amsacrine (Amsa PD/Amekrin)
14.10 Immune Globulin (Gammagard Liquid, Gammagard S/D, Cuvitru & HyQvia)
14.11 Crisantaspase (Erwinase)
14.12 Pegaspargase (Oncaspar)
14.13 Calaspargase Pegol (Asparlas)
14.14 Asparaginase (Elspar/Kidrolase/Leunase)
14.15 Sobuzoxane (Perazolin)
- MultiKinase Inhibitor Drugs for Leukemia – Availability, Dosage, & Price Analysis
15.1 Gilteritinib (Xospata)
- Tyrosine Kinase Inhibitors for Leukemia – Availability, Dosage, & Price Analysis
16.1 Bosutinib (Bosulif)
16.2 Dasatinib (Sprycel)
16.3 Ponatinib (Iclusig)
16.4 Nilotinib (Tasigna)
16.5 Quizartinib (Vanflyta)
16.6 Radotinib (Supect)
16.7 Imatinib (Gleevec)
- Combinational Antineoplastic Drugs for Leukemia – Availability, Dosage & Price Analysis
17.1 Cytarabine/Daunorubicin (Vyxeos)
17.2 Ivosidenib (Tibsovo)
17.3 Rituxan Hycela (hyaluronidase/rituximab)
- Antimetabolites for Leukemia – Availability, Dosage & Price Analysis
18.1 Cladribine (Mavenclad/Leustatin)
18.2 Clofarabine (Clolar)
18.3 Mercaptopurine Oral Suspension (Purixan)
18.4 Methotrexate Oral Solution (Xatmep)
18.5 Decitabine (Decogen)
18.6 Nelarabine (Arranon)
18.7 Fludarabin (Fludara/Oforta)
18.8 Methotrexate
- Anticancer Antibiotics for Leukemia – Availability, Dosage & Price Analysis
19.1 Pentostatin (Nipent)
19.2 Mitoxantrone (Novantrone)
19.3 Idarubicin (Idamycin)
- Phosphoinositide 3-Kinase Inhibitors – Availability, Dosage & Price Analysis
20.1 Duvelisib (Copiktra)
20.2 Idelalisib (Zydelig)
- Alkylating Agents for Leukemia – Availability, Dosage & Price Analysis
21.1 Bendamustine (Treanda/Belrapzo/Bendeka)
21.2 Cyclophosphamide
21.3 Dianhydrogalactitol (DAG for Injection)
- Bruton Tyrosine Kinase (BTK) Inhibitors for Leukemia – Availability, Dosage, & Price Analysis
22.1 Ibrutinib (Imbruvica)
- Monoclonal Antibodies for Leukemia – Availability, Dosage, & Price Analysis
23.1 Inotuzumab ozogamicin (Besponsa)
23.2 Gemtuzumab ozogamicin (Mylotarg)
23.3 Ofatumumab (Arzerra)
23.4 Gazyva (Obinutuzumab)
23.5 MabThera/Rituxan (Rituximab)
23.6 Blinatumomab (Blincyto)
23.7 Lumoxiti (Moxetumomab pasudotox)
23.8 Poteligeo (Mogamulizumab)
23.9 Rituximab Biosimilar (Truxima)
23.10 Rituximab Biosimilar (Ruxience)
23.11 Rituximab Biosimilar (Rixathon)
23.12 Rituximab Biosimilar – Acellbia
23.13 Rituximab Biosimilar – Maball
23.14 Rituximab Biosimilar – Mabtus
23.15 Rituximab Biosimilar – Zytux
23.16 Alemtuzumab (Campath)
- T-Cell Therapy for Leukemia – Availability, Dosage, & Price Analysis
24.1 Tisagenlecleucel (Kymriah)
24.2 Nalotimagene Carmaleucel (Zalmoxis)
- Mitotic Inhibitors for Leukemia – Availability, Dosage & Price Analysis
25.1 Vincristine Liposomal (Marqibo)
- Antineoplastic Interferons for Leukemia – Availability, Dosage & Price Analysis
26.1 Interferon Alpha-2b (Intron A)
26.2 Interferon Alfa-2a (Roferon-A/Veldona)
26.3 Interferon Alpha (Multiferon)
- Global Leukaemia Drug Clinical Pipeline By Company, Indication & Phase
27.1 Unknown
27.2 Research
27.3 Preclinical
27.4 Clinical
27.5 Phase-0
27.6 Phase-I
27.7 Phase-I/II
27.8 Phase-II
27.9 Phase-II/III
27.10 Phase-III
27.11 Preregistration
27.12 Registered
- Global Marketed Leukaemia Drug Clinical Insight
- Global Leukemia Therapeutics Market Dynamics
29.1 Global Leukemia Therapeutics Growth Attributors
29.2 Challenges Concerning the Growth of Leukemia Therapeutics Market at Global
Level
- Global Leukemia Therapeutics Market Future Insights
- Competitive Landscape
31.1 AbbVie Inc
31.2 Bristol-Myers Squibb
31.3 Amgen
31.4 Genzyme Corporation
31.5 Pfizer
31.6 GlaxoSmithKline Plc
31.7 Novartis International AG
31.8 Teva Pharmaceuticals
31.9 Takeda Pharmaceuticals
31.10 Piramal Pharma Solutions
Contact:
Rajesh Arora
rajesh@pnspharma.com
+91-09811484754